Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.
about
Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapyInfliximab-Associated Psoriasiform Dermatitis: Case Report and Review of a Seemingly Paradoxical Inflammatory Response.A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease.Adverse Events During Anti-TNFα Therapies in IBD (Excluding Infections and Malignancies): When to Stop, Continue, or Switch Therapies.Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience.Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease - a nested case-control study.Clinical Signs, Pathophysiology and Management of Cutaneous Side Effects of Anti-Tumor Necrosis Factor Agents.Novel posterior auricular cutaneous reaction after anti-TNF-α infusion in young women with Crohn's disease.Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.Infliximab-induced acne and acute localized exanthematous pustulosis: Case report.Tumour necrosis factor-α-inhibitor-induced neutrophilic folliculitis presenting with strong lesional expression of interleukin-36γ.Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients.Cholinergic Anti-Inflammatory Pathway Does Not Contribute to Prevention of Ulcerative Colitis by Novel Indoline Carbamates.New onset vitiligo following commencement of infliximab in Crohn disease.
P2860
Q28067631-BE851E2C-09D6-4FBB-B903-41EE90C08B84Q37329074-1E8D8CDA-8784-4C36-8AA7-B23F1F620023Q38707864-588EE584-234C-4D7D-BB51-1F8219401093Q38751610-14ECAD3E-8C57-44EC-A463-9F0EFF99DBF9Q38883385-9E3CD622-D240-4ECC-8EB5-45A3E44896C2Q38977555-8DD2200B-6EC4-401B-AA3C-025280C4E721Q39361308-AFB739F0-3968-4048-AEA7-A2DFBF90A19DQ47142776-417C1B9E-2D9C-47C3-B3DF-1B9F159389F0Q48102896-A7D2E253-1344-49F9-97C3-3FACA7D710AEQ48246171-E355E81A-FD4B-4CBE-AF5C-D7BF6EA4AE71Q48282383-23E9CC76-1B71-4283-BAA2-F13C1FD456A3Q49970991-378A561A-EFB2-4B78-A0D5-ACBD0068D242Q51107226-A22019F2-9128-45FD-86CD-434B88C425E6Q53123158-59199A70-C6F5-4E5F-B5C8-16EFC0DC9B0E
P2860
Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Cumulative incidence of, risk ...... disease: a 14-year experience.
@en
type
label
Cumulative incidence of, risk ...... disease: a 14-year experience.
@en
prefLabel
Cumulative incidence of, risk ...... disease: a 14-year experience.
@en
P2093
P356
P1476
Cumulative incidence of, risk ...... disease: a 14-year experience.
@en
P2093
Annick Barbaud
Cédric Baumann
Estelle Fréling
Jean-François Cuny
Jean-Luc Schmutz
Marc-André Bigard
P304
P356
10.1038/AJG.2015.205
P407
P577
2015-07-21T00:00:00Z